These posters highlight key data supporting the rationale for the Phase 1b program in biomarker-selected cancers as a single agent, and in combination with market leading therapies to overcome ...

Sonoma Biotherapeutics Announces Oral and Poster Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting Sonoma Biotherapeutics, Inc., a clinical-stage ...

Session A-2 Room 339: Leverage AI in Psychology: Finding a Use Case Presentation 1: Finding a Use Case: Building a Scheduling GPT: Olivia Velez, Psychology Presentation 2: Finding a Use Case: Natural ...

Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the ...

30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY. Details of the oral and poster presentation are as follows: ...

The poster, titled “Outer Retina-Choroid en ... Ophthalmology of MERIT. About the Presentation: • Title: “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic ...

These posters highlight key data supporting the ... “This year’s AACR presentations mark an important milestone in the development of NXP900. As new preclinical data continue to unlock the ...

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...